Dr. Peter Pedersen Explaining the Promise of 3-BP

http://videocast.nih.gov/summary.asp?live=7542

The above link is of Dr. Peter Pedersen in a NIH/NCI presentation on the exploitation of hexokinase II by 3-BP.  Dr. Pedersen is an exemplary research scientist who is doing the ‘heavy-lifting’, the gritty, molecular details of cancer’s defective metabolism.  When you watch the video it is impossible to not get excited about this new compound.  (If you feel sorry for the mice that researchers use to study cancer — then this video will make you feel better, because in Dr. Pedersen’s lab, the mice don’t die, they just get cured.)

7 thoughts on “Dr. Peter Pedersen Explaining the Promise of 3-BP

  1. Gordon T. Emerson

    Hello Travis : Thanks for the chat today. I hope to get better informed on the Ketogenic research and associated efforts leading up to presentations to some Foundations in Canada.

    Reply
  2. matthew

    thanks for the great info – I plan on following the developments EITHER WAY – as they occur truth is what we’re all after thanks again

    Reply
  3. Edward Miller

    The video is striking in two ways.

    The first is the substance, a really exciting set of results, the most optimistic I know of.

    The second is the size of the audience. It is in a conference room and most seats around the table are vacant. I would have expected this to be at a major medical conference as the keynote speech, in a large lecture hall, and with standing room only.

    There should be loud cheering, but there is none.

    Reply
  4. skip

    Also a good resource Thomas Seyfried’s book: cancer is a metabolic disease. Expensive but super high quality. Anyone whose cancer treatment is failing should grab it.

    Reply
  5. Danilo

    Just for info, the recent doc. “A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models” ( http://www.ncbi.nlm.nih.gov/pubmed/26259240 ) compares 9 inhibitors (Phloretin, Quercetin, STF31, WZB117, 3PO, 3-bromopyruvate, Dichloroacetate, Oxamic acid, NHI-1) in breast and ovarian cancer cell line models.
    About Glycolytic inhibitors induced apoptosis, “Untreated cells showed 7% apoptosis (Annexin positive)
    whereas for cells treated with 300 μM Phloretin the percentage of apoptotic cells increased to 43%,
    with 300 μM Quercetinto 25%,
    with 30 μM STF31 to 29%,
    with 30 μM WZB117 to 11%,
    with 300 μM 3BP to 92%,
    with 30 μM 3PO to 28%,
    with 100mM DCA to 58%,
    with 300 μM NHI-1 to 47% and
    with 100mM Oxamic acid to 13%”

    Reply
  6. Emma

    Can anyone let me know what the current situation is
    with the clinical trials of 3BP and RKD with Hyberbaric O2?
    Has funding been raised yet?

    Reply
  7. Greg Grange

    I do not see a reply to Emma’s question above. I am very curious about why clinical trials with 3BP don’t seem to be advancing. Anybody have any answers?

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *